Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients

Neuropathology

Volumn 31, Issue 4, 2011, Pages 376-383

  Srividya, Mallavarapu R ^a   Thota, Balaram ^a   Shailaja, Bangalore C ^a   Arivazhagan, Arimappamagan ^a   Thennarasu, Kandavel ^b   Chandramouli, Bangalore A ^a   Hegde, Alangar S ^c   Santosh, Vani ^a  

^a Department of Neuropathology ^*  (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

Author keywords

Glioblastoma; Homozygous deletion; Phosphatase and tensin homolog deleted on chromosome 10; Prognosis; Survival

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME LOSS; COHORT ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENETIC ASSOCIATION; GLIOBLASTOMA; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; GENE DOSAGE; GLIOBLASTOMA; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS;

EID: 79960722502     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2010.01178.x     Document Type: Article

References (61)

1. Louis DN, Wiestler OD, Burger PC, Schiethauer BW. WHO grading of tumors of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD etal, eds. WHO Classification of Tumors of the Central Nervous System, 4th edn. Lyon: IARC Press, 2007; 10-11.
2. Kleihues P, Louis DN, Scheithauer BW etal. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225.
3. Furnari FB, Fenton T, Bachoo RM etal. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710.
4. Godard S, Getz G, Delorenzi M etal. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003; 63: 6613-6625.
5. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009; 100: 2235-2241.
6. Kanu OO, Hughes B, Di C etal. Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 2009; 3: 39-52.
7. Kim DH, Mohapatra G, Bollen A etal. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 1995; 60: 812-819.
8. Mohapatra G, Bollen AW, Kim DH etal. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 1998; 21: 195-206.
9. Nishizaki T, Ozaki S, Harada K etal. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 1998; 21: 340-346.
10. von Deimling A, Fimmers R, Schmidt MC etal. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000; 59: 544-558.
11. Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004; 75 (Suppl 2): ii2-i11.
12. Vranová V, Necesalová E, Kuglík P etal. Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization. Oncol Rep 2007; 17: 457-464.
13. Ohgaki H, Dessen P, Jourde B etal. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
14. Rasheed BK, McLendon RE, Friedman HS etal. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995; 10: 2243-2246.
15. Karlbom AE, James CD, Boethius J etal. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993; 92: 169-174.
16. Ichimura K, Schmidt EE, Miyakawa A etal. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998; 22: 9-15.
17. Fujisawa H, Reis RM, Nakamura M etal. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000; 80: 65-72.
18. Fults D, Pedone CA, Thompson GE etal. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998; 12: 905-910.
19. Kleihues P, Cavenee WK. Pathology and genetics of tumors of the nervous system. In: Louis DN, Ohgaki H, Wiestler OD etal, eds. WHO Classification of Tumors of the Central Nervous System, 4th edn. Lyon: IARC Press, 2007; 10-21.
20. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
21. Vogt PK. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 2001; 7: 482-484.
22. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000; 7: 115-129.
23. Knobbe CB, Merlo A, Reifenberger G. Pten signaling in gliomas. Neuro-oncol 2002; 4: 196-211.
24. Li J, Yen C, Liaw D etal. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
25. Duerr EM, Rollbrocker B, Hayashi Y etal. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16: 2259-2264.
26. Steck PA, Pershouse MA, Jasser SA etal. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
27. Boström J, Cobbers JM, Wolter M etal. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998; 58: 29-33.
28. Rasheed BK, Stenzel TT, McLendon RE etal. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 1997; 57: 4187-4190.
29. Schmidt EE, Ichimura K, Goike HM etal. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 1999; 58: 1170-1183.
30. Tohma Y, Gratas C, Biernat W etal. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57: 684-689.
31. Wang SI, Puc J, Li J etal. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997; 57: 4183-4186.
32. Sasaki H, Zlatescu MC, Betensky RA etal. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001; 159: 359-367.
33. Smith JS, Tachibana I, Passe SM etal. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246-1256.
34. Zhou XP, Li YJ, Hoang-Xuan K etal. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999; 84: 150-154.
35. Lin H, Bondy ML, Langford LA etal. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 1998; 4: 2447-2454.
36. Tada K, Shiraishi S, Kamiryo T etal. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 2001; 95: 651-659.
37. Sano T, Lin H, Chen X etal. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999; 59: 1820-1824.
38. Korshunov A, Sycheva R Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age <50 Years. Cancer 2005; 104: 825-832.
39. Korshunov A, Sycheva R, Gorelyshev S etal. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005; 18: 1258-1263.
40. Simmons ML, Lamborn KR, Takahashi M etal. Analysis of complex association between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61: 1122-1128.
41. Batchelor TT, Betensky RA, Esposito JM etal. Age-dependant prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10: 228-233.
42. Srividya MR, Thota B, Arivazhagan A etal. Age-dependent prognostic effects of EGFR/p53 alterations in glioblastoma: study on a prospective cohort of 140 uniformly treated adult patients. J Clin Pathol 2010; 63 (8): 687-691.
43. Mezzelani A, Alasio L, Bartoli C etal. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999; 80: 519-525.
44. Kawai T, Hiroi S, Nakanishi K etal. Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int 2004; 54: 413-419.
45. Ventura RA, Martin-Subero JI, Jones M etal. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006; 8: 141-151.
46. Yoshimoto M, Cunha IW, Coudry RA etal. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-685.
47. Kleihues P, Burger PC, Aldape KD etal. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK etal, eds. WHO Classification of Tumors of the Central Nervous System, 4th edn. Lyon: IARC Press, 2007; 33-49.
48. Chang H, Qi XY, Claudio J etal. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006; 30: 262-265.
49. Brat DJ, Seiferheld WF, Perry A etal. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro Oncol 2004; 6: 96-103.
50. Fuller CE, Schmidt RE, Roth KA etal. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 2003; 62: 1118-1128.
51. Fuller CE, Wang H, Zhang W etal. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J Neuropathol Exp Neurol 2002; 61: 1078-1084.
52. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin Cancer Res 2004; 10: 7820-7826.
53. Perry A, Aldape KD, George DH etal. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004; 101: 2318-2326.
54. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124-2129.
55. Myers MP, Stolarov JP, Eng C etal. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997; 94: 9052-9057.
56. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
57. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999; 9: 125-128.
58. Ichimura K, Ohgaki H, Kleihues P etal. Molecular pathogenesis of brain tumors. J Neurooncol 2004; 70: 137-160.
59. Jalali R, Basu A, Gupta T etal. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Br J Neurosurg 2007; 21: 583-587.
60. Chang CH, Horton J, Schoenfeld D etal. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52: 997-1007.
61. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 2000; 5: D213-D231.